News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Tryptamine Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Canary Capital sees explosive potential in Exopharm
Health & Biotech
Nanoveu says there are other ways to clean your phone from corona, shares fly
Health & Biotech
Are we mortgaging the future as COVID-19 closes clinical trials?
Health & Biotech
Biotech: It’s not a get-rich-quick scheme judging by these HY reports
Health & Biotech
Biotech: Exopharm arouses market over potential to treat erectile dysfunction
News
Health: Is this company onto an alternative to stem cell therapy?
Health & Biotech
Health: New US guidelines on breast cancer may help this ASX biotech
Health & Biotech
Cann pulls back from Mildura pot project as world flooded with weed
Health & Biotech
Health: Poor pigs and dairy performance offsets feedlot wins at Apiam
Health & Biotech
There’s a bit of promise for health small caps in the federal Budget – but there’s also a big ‘if’
Health & Biotech
Health: Neurotech fires a strategic adviser after claims he’s a dud, shares fall 17pc
IPO Watch
IPO Watch: Uniti Wireless set to ring the ASX bell today; four contenders take their mark
News
Capital crunch hits ASX as fundraisings plunge 34pc
IPO Watch
IPOs of 2018: The few that floated when most didn’t
IPO Watch
